Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily ...
Breadcrumb Trail Links GlobeNewswire Author of the article: Published Oct 17, 2024 • 5 minute read Article content Baseline Data Show More Frequent Selection of Ibalizumab in Patients with Lower CD4 Counts and Higher Viral Loads, Compared to Other …